Singapore, Jan. 9 -- Ribo Life Science Co., a leading company in small interfering RNA (siRNA) therapeutics, has successfully listed on the Main Board of Hong Kong Stock Exchange, marking a significant milestone in the capitalisation of Chinese biopharmaceutical enterprises in the siRNA field and injecting new momentum into the industry.

In its global offering, Ribo issued a total of 31,610,400 shares at an offer price of HKD 57.97 per share, raising gross proceeds of over 1.8 billion Hong Kong dollars, HKPO was over 100x oversubscribed, International Placingwas 16.7x oversubscribed, reflecting strong global investor confidence in the value of the siRNA sector and the company's capabilities.

The IPO proceeds will provide solid financial...